<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664556</url>
  </required_header>
  <id_info>
    <org_study_id>IPD</org_study_id>
    <nct_id>NCT04664556</nct_id>
  </id_info>
  <brief_title>Invasive Pneumococcal Disease Study</brief_title>
  <official_title>Population-based Nationwide Study on Invasive Pneumococcal Infections Among Children (0-18 Years) in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Clinique Thérapeutique Infantile du val de Marne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Clinique Thérapeutique Infantile du val de Marne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After 7 then 13 valent pneumococcal conjugate vaccine implementation in France in children,&#xD;
      we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We&#xD;
      will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying&#xD;
      conditions and vaccination status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of invasive pneumococcal disease</measure>
    <time_frame>before hospital discharge</time_frame>
    <description>Number of severe cases according to age and pneumococcal serotypes distribution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of vaccines</measure>
    <time_frame>before hospital discharge</time_frame>
    <description>Number of invasive pneumococcal disease according to vaccine serotypes</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1205</enrollment>
  <condition>Pneumococcal Infections</condition>
  <condition>Pneumococcal Conjugate Vaccine</condition>
  <condition>Antibiotic Treatment</condition>
  <condition>Mortality</condition>
  <arm_group>
    <arm_group_label>Cohort of invasive pneumococcal disease in children</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational study</intervention_name>
    <description>observational study</description>
    <arm_group_label>Cohort of invasive pneumococcal disease in children</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with invasive pneumococcal disease for whom the pneumococcal strain is sent to the&#xD;
        National reference Center for Pneumococci for serotyping&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid,&#xD;
             or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if&#xD;
             there is a positive blood PCR.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>ACTIV</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Levy, MD</last_name>
      <phone>0033148850404</phone>
      <email>corinne.levy@activ-france.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphane Béchet, MsC</last_name>
      <phone>0033148850404</phone>
      <email>stephane.bechet@activ-france.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ACTIV</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Levy, MD</last_name>
      <phone>0033148850404</phone>
      <email>corinne.levy@activ-france.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphane Béchet, MSc</last_name>
      <phone>0033148850404</phone>
      <email>stephane.bechet@activ-france.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1093/cid/ciaa917</url>
    <description>Invasive Disease Potential of Pneumococcal Serotypes in Children After PCV13 Implementation</description>
  </link>
  <link>
    <url>https://doi.org/10.1093/cid/ciz221</url>
    <description>Changes in Invasive Pneumococcal Disease Spectrum After 13-Valent Pneumococcal Conjugate Vaccine Implementation</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

